Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Albuminuria and Decline in Cognitive Function

Albuminuria and Decline in Cognitive Function ORIGINAL INVESTIGATION The ONTARGET/TRANSCEND Studies Joshua I. Barzilay, MD; Peggy Gao, MSc; Martin O’Donnell, MD, PhD; Johannes F. E. Mann, MD; Craig Anderson, MD, PhD; Robert Fagard, MD, PhD; Jeffrey Probstfield, MD; Gilles R. Dagenais, MD; Koon Teo, MD, PhD; Salim Yusuf, MD, DPhil; for the ONTARGET and TRANSCEND Investigators Background: Microvascular disease of the kidney (mani- cognitive decline (decrease in MMSE score 3 points) festing as albuminuria) and of the brain (manifesting as compared with those with normoalbuminuria (microal- cognitive decline) may share a common pathogenesis. buminuria: OR, 1.22; 95% CI, 1.07-1.38; macroalbumin- Gaining an understanding of the concomitant history of uria: 1.21; 0.94-1.55). Participants who developed new these 2 conditions may inform clinical practice and lead albuminuria had increased odds of cognitive decline dur- to novel prevention and treatment approaches. ing follow-up compared with those who remained nor- moalbuminuric (new microalbuminuria: OR, 1.30; 95% Methods: A total of 28 384 participants with vascular dis- CI, 1.12-1.52; new macroalbuminuria: 1.77; 1.24- ease or diabetes mellitus were examined. At baseline and 2.54). Participants with baseline macroalbuminuria treated year 5, participants underwent a Mini-Mental State Exami- with an angiotensin-converting enzyme inhibitor and/or nation (MMSE) and urine testing for albumin excretion. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Albuminuria and Decline in Cognitive Function

Download PDF
9 pages

Loading next page...
 
/lp/american-medical-association/albuminuria-and-decline-in-cognitive-function-B9GLlFfkRu

References (36)

Publisher
American Medical Association
Copyright
Copyright 2011 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinternmed.2010.502
pmid
21263104
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL INVESTIGATION The ONTARGET/TRANSCEND Studies Joshua I. Barzilay, MD; Peggy Gao, MSc; Martin O’Donnell, MD, PhD; Johannes F. E. Mann, MD; Craig Anderson, MD, PhD; Robert Fagard, MD, PhD; Jeffrey Probstfield, MD; Gilles R. Dagenais, MD; Koon Teo, MD, PhD; Salim Yusuf, MD, DPhil; for the ONTARGET and TRANSCEND Investigators Background: Microvascular disease of the kidney (mani- cognitive decline (decrease in MMSE score 3 points) festing as albuminuria) and of the brain (manifesting as compared with those with normoalbuminuria (microal- cognitive decline) may share a common pathogenesis. buminuria: OR, 1.22; 95% CI, 1.07-1.38; macroalbumin- Gaining an understanding of the concomitant history of uria: 1.21; 0.94-1.55). Participants who developed new these 2 conditions may inform clinical practice and lead albuminuria had increased odds of cognitive decline dur- to novel prevention and treatment approaches. ing follow-up compared with those who remained nor- moalbuminuric (new microalbuminuria: OR, 1.30; 95% Methods: A total of 28 384 participants with vascular dis- CI, 1.12-1.52; new macroalbuminuria: 1.77; 1.24- ease or diabetes mellitus were examined. At baseline and 2.54). Participants with baseline macroalbuminuria treated year 5, participants underwent a Mini-Mental State Exami- with an angiotensin-converting enzyme inhibitor and/or nation (MMSE) and urine testing for albumin excretion.

Journal

JAMA Internal Medicine – American Medical Association

Published: Jan 24, 2011

There are no references for this article.